Condition: Hemodialysis · Peritoneal Dialysis · Hypercholesterolemia · Sponsor: Baylor Research Institute
12-week study of the efficacy and safety of alirocumab in patients maintained stably on hemodialysis or peritoneal dialysis. Measures of cholesterol levels, drug levels, PCSK9 levels, routine chemistry and cell counts, and biomarkers will be obtained at baseline and at weeks 4, 8, 10 and 12 weeks. Safety events will be obtained throughout the study.
This description comes directly from the study's public registry record.
Cara East, MD · 214-820-2273 · cara.east@bswhealth.org
Merielle Boatman · 214-820-2273 · merielle.boatman@bswhealth.org
Always discuss trial participation with your own doctor first.
| Baylor Soltero CV Research | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03480568